LONDON--(BUSINESS WIRE)--May 16, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat anaplastic thyroid cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005580/en/

Technavio has published a new pipeline analysis report on the global anaplastic thyroid cancer market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time only:

Save more with Technavio. Buy2 reports and get the third for FREE:

Anaplastic thyroid cancer - market overview

is also called as the “anaplastic thyroid carcinoma.” It is one of the fastest growing thyroid cancers. It is also known as undifferentiated thyroid cancer, as the cells do not look or behave like typical thyroid cells. Anaplastic thyroid cancer typically starts within the thyroid as growth or bump in the thyroid that quickly grows out of the otherwise normal thyroid tissue. This type of cancer spreads very rapidly.

According to a senior analyst at Technavio for , “Anaplastic thyroid cancer is an uncommon tumor and accounts for only 2%-5% of total thyroid tumors. This type of tumor emerges from the follicular cells of the thyroid gland.”

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Anaplastic thyroid cancer segmentation

This market research report segments the market based on therapies employed that includes monotherapy and combination therapy, RoA (oral and intravenous), therapeutic modalities (small molecules and monoclonal antibody), targets for drugs under development (interleukin (IL), glucocorticoid receptor (GCR), and undisclosed), drugs under development (phase I, phase I/II, phase II, and pre-clinical), indications covered (anaplastic thyroid cancer and metastatic anaplastic thyroid cancer). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005580/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 05/16/2018 06:15 AM/DISC: 05/16/2018 06:15 AM

http://www.businesswire.com/news/home/20180516005580/en